Early-onset type 2 diabetes and kidney disease in a growing surgical generation: insights from a global burden analysis

Dear Editor, Zhang et al use Global Burden of Disease (GBD) 2021 data to describe the burden, temporal trends, and forecasts of early-onset type 2 diabetes (T2DM) and diabetes-related chronic kidney disease (CKD-T2DM) in people aged 15–39 years[1]. They report steadily rising disability-adjusted life years (DALYs) and age-standardized DALY rates (ASDRs) for early-onset T2DM, a more modest increase in CKD-T2DM DALYs, and declining CKD-T2DM ASDRs, with high body mass index (BMI) responsible for more than half of DALYs for both conditions and marked variation across sociodemographic index (SDI) strata[1]. This study gives a clear, data-driven picture of how two tightly linked conditions are evolving in younger adults. Several aspects of the work are worth highlighting. Analyzing early-onset T2DM and CKD-T2DM within the same framework allows direct comparison of trajectories for the primary disease and its renal complication rather than treating them as separate epidemics[1]. The authors apply complementary tools-joinpoint regression, age-period-cohort modeling, decomposition methods, and ARIMA forecasting-to separate epidemiological change from demographic effects and to extend current trends to 2036 under a “status quo” assumption[1]. By quantifying the contributions of high BMI and high fasting glucose and describing SDI-specific patterns, the study generates concrete signals that can inform obesity prevention, diabetes management, and health-service planning[1]. The results are largely in line with, and refine, recent work on young-onset diabetes and diabetes-related kidney disease. Global analyses have already shown sharp increases in T2DM among adolescents and young adults, with high burdens in middle-SDI regions and in young women, and substantial geographical heterogeneity[2,3]. Parallel studies report that diabetes-related CKD is rising worldwide, including among younger adults, and is an important driver of demand for kidney replacement therapy[4]. By focusing explicitly on the 15–39-year age band, contrasting early-onset T2DM and CKD-T2DM within the same GBD framework, and providing medium-term forecasts, Zhang et al add granularity that is directly relevant for planning capacity for metabolic surgery, dialysis, and transplantation[1]. Their discussion of metabolic surgery as part of an obesity strategy is also timely, given growing evidence that bariatric procedures can deliver durable glycemic control and quality-of-life gains in people with obesity-related T2DM[5]. In our view, some caveats are important when moving from these estimates to policy or clinical decisions. All figures arise from GBD modeling and depend on input data of variable completeness and quality, especially in low-SDI settings where diagnostic coverage and cause-of-death information may be limited[1,4]. “Early-onset T2DM” is defined by chronological age (15–39 years) rather than by age at diagnosis or disease duration, so true early-onset cases cannot be distinguished from long-standing diabetes first documented in young adulthood[1]. DALY-based measures, while appropriate where mortality data are sparse, do not capture CKD stage, albuminuria, or episodes of acute kidney injury, and may under-represent multimorbidity[4]. ARIMA forecasts, by design, extrapolate past patterns and cannot easily incorporate sudden shifts such as rapid uptake of GLP-1 receptor agonists and dual incretin therapies, evolving eligibility criteria for metabolic surgery, or major economic and policy shocks[1,2]. Further work could build on these findings in several ways. First, linking GBD-based estimates with national clinical registries, insurance claims, and surgical databases would help validate incidence and progression patterns of early-onset T2DM and CKD-T2DM and uncover within-country inequalities that national aggregates obscure[1–4]. Second, comparative modeling that incorporates realistic scenarios for the expansion of metabolic surgery and kidney-protective pharmacotherapy could clarify how different prevention and treatment packages might alter the projected burden and guide workforce planning for bariatric, vascular, and transplant services[4,5]. Third, a more explicit life-course perspective – integrating early-life under- and over-nutrition, physical inactivity, and environmental pollution – may improve targeting of prevention strategies for adolescents and young adults who are most likely to become future surgical candidates[2–4]. Overall, Zhang et al provide a concise and policy-relevant overview of the current and projected burden of early-onset T2DM and diabetes-related CKD in people aged 15–39 years[1]. Their analysis reinforces high BMI as a major but modifiable driver and reveals SDI-specific patterns that can support differentiated prevention and treatment strategies[1–4]. For the surgical community, these data underline the need to view metabolic and bariatric surgery, renal replacement therapies, and perioperative optimization as linked components of a life-course approach to diabetes-related kidney disease in younger generations[4,5].